Geode Capital Management
CUE icon

Geode Capital Management’s Cue Biopharma CUE Stock Holding History

Geode Capital Management’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$245K Buy
35,490
+8,714
+33% +$81.3K ﹤0.01% 3855
2025
Q4 		$245K Buy
26,776
+84
+0.3% +$1.54K ﹤0.01% 3843
2025
Q3 		$576K Buy
26,692
+3,620
+16% +$85K ﹤0.01% 3565
2025
Q2 		$472K Sell
23,072
-58
-0.3% -$1.24K ﹤0.01% 3572
2025
Q1 		$632K Buy
23,130
+2,087
+10% +$77.5K ﹤0.01% 3460
2024
Q4 		$688K Buy
21,043
+4,082
+24% +$153K ﹤0.01% 3495
2024
Q3 		$385K Buy
16,961
+546
+3% +$11.8K ﹤0.01% 3693
2024
Q2 		$611K Sell
16,415
-11,536
-41% -$571K ﹤0.01% 3496
2024
Q1 		$1.59M Buy
27,951
+841
+3% +$59.3K ﹤0.01% 3202
2023
Q4 		$2.15M Buy
27,110
+1,696
+7% +$121K ﹤0.01% 3075
2023
Q3 		$1.75M Buy
25,414
+1,099
+5% +$107K ﹤0.01% 3113
2023
Q2 		$2.66M Buy
24,315
+9,223
+61% +$1.08M ﹤0.01% 3022
2023
Q1 		$1.62M Buy
15,092
+4,564
+43% +$435K ﹤0.01% 3122
2022
Q4 		$900K Buy
10,528
+574
+6% +$52.5K ﹤0.01% 3392
2022
Q3 		$665K Buy
9,954
+18
+0.2% +$1.55K ﹤0.01% 3584
2022
Q2 		$742K Sell
9,936
-8,344
-46% -$976K ﹤0.01% 3554
2022
Q1 		$2.68M Buy
18,280
+900
+5% +$191K ﹤0.01% 3105
2021
Q4 		$5.9M Sell
17,380
-2,700
-13% -$1.04M ﹤0.01% 2804
2021
Q3 		$8.78M Buy
20,080
+2,869
+17% +$1M ﹤0.01% 2546
2021
Q2 		$6.01M Buy
17,211
+1,009
+6% +$391K ﹤0.01% 2792
2021
Q1 		$5.93M Buy
16,202
+1,847
+13% +$760K ﹤0.01% 2703
2020
Q4 		$5.39M Buy
14,355
+1,301
+10% +$520K ﹤0.01% 2565
2020
Q3 		$5.89M Buy
13,054
+479
+4% +$276K ﹤0.01% 2295
2020
Q2 		$9.25M Buy
12,575
+2,289
+22% +$1.66M ﹤0.01% 1961
2020
Q1 		$4.38M Buy
10,286
+1,512
+17% +$733K ﹤0.01% 2223
2019
Q4 		$4.18M Buy
8,774
+1,750
+25% +$550K ﹤0.01% 2571
2019
Q3 		$1.78M Buy
7,024
+186
+3% +$44.7K ﹤0.01% 3003
2019
Q2 		$1.84M Buy
6,838
+1,965
+40% +$489K ﹤0.01% 3003
2019
Q1 		$1.13M Buy
4,873
+508
+12% +$96.6K ﹤0.01% 3118
2018
Q4 		$615K Buy
4,365
+497
+13% +$90.2K ﹤0.01% 3293
2018
Q3 		$1.05M Buy
3,868
+211
+6% +$61K ﹤0.01% 3201
2018
Q2 		$1.3M Buy
3,657
+1,283
+54% +$510K ﹤0.01% 3073
2018
Q1 		$1M Buy
+2,374
New +$1.08M ﹤0.01% 3125

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
GWMR
GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return

Geode Capital Management's CUE Position: Q1 2026 in Review

Geode Capital Management increased its Cue Biopharma (CUE) stake by 33% in Q1 2026, buying an estimated $81.3K and bringing the position to 35,490 shares worth $245K. The position accounts for ﹤0.01% of the portfolio, ranked #3855.

Geode Capital Management first reported a position in CUE in Q1 2018 and has held it in 33 quarters since. The position peaked at $9.25M in Q2 2020. 55 funds tracked by Wall St. Rank hold CUE as of Q1 2026.

  • Geode Capital Management held 35,490 shares of Cue Biopharma worth $245K as of Q1 2026.
  • Geode Capital Management bought 8,714 Cue Biopharma shares in Q1 2026, an estimated $81.3K.
  • Cue Biopharma made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3855 holding.
  • Geode Capital Management first reported a position in Cue Biopharma in Q1 2018 and has held it in 33 quarters since.
  • Geode Capital Management's Cue Biopharma position peaked at $9.25M in Q2 2020.
  • 55 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.